US court urged to revamp inequitable conduct doctrine in patent litigation
This article was originally published in RAJ Devices
Executive Summary
A US court has been urged to revamp the inequitable conduct doctrine, a commonly used provision in patent litigation that allows the validity of a patent to be challenged if one is able to establish that, at the time of applying for a patent, the applicant had wilfully given misleading statements or had withheld material information with the intention to deceive the Patent and Trademark Office1.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.